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Objectives The purpose of this prospective registry was to evaluate the safety and efficacy, at 1 year, of the use of drug-
eluting balloons (DEB) for the treatment of superficial femoral artery (SFA) in-stent restenosis (ISR).
Background The use of the self-expanding nitinol stent has improved the patency rate of SFA after percutaneous translumi-
nal angioplasty (PTA). As the population with SFA stenting continues to increase, occurrence of ISR has become
a serious problem. The use of DEB has showed promising results in reducing restenosis recurrence in coronary
stents.
Methods From December 2009 to December 2010, 39 consecutive patients underwent PTA of SFA-ISR in our institution.
All patients underwent conventional SFA PTA and final post-dilation with paclitaxel-eluting balloons (IN.PACT,
Medtronic, Minneapolis, Minnesota). Patients were evaluated up to 12 months.
Results Technical and procedural success was achieved in every patient. No in-hospital major adverse cardiac and cere-
brovascular events occurred. At 1 year, 1 patient died due to heart failure. Primary endpoint, primary patency
rate at 12 months, was obtained in 92.1% (35 patients). At 1 year, patients were asymptomatic for claudication,
and duplex assessment demonstrated lack of recurrent restenosis (100% rate of Secondary patency). The pres-
ence of an occlusive restenosis at the time of treatment was not associated with an increased restenosis rate,
when compared with non-occlusive restenosis, at 1 year.
Conclusions The data suggest that adjunctive use of DEB for the treatment of SFA-ISR represents a potentially safe and ef-
fective therapeutic strategy. These data should be considered hypothesis-generating to design a randomized
trial. (J Am Coll Cardiol 2012;60:1739–42) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.033Endovascular therapy for superficial femoral artery (SFA)
disease has been recognized as a safe and efficient therapy
(1). The patency rate of treated SFA has been improved
through use of the self-expanding nitinol stents (2–4). As
the population with SFA stenting continues to increase,
occurrence of in-stent restenosis (ISR) has become a
thoughtful problem. Treatment of SFA-ISR is associated
with increased risks of recurrent ISR, recurrent occlusion,
and surgical revascularization when compared with focal or
diffuse restenosis (5). No standard treatment exists for the
treatment of SFA-ISR.
The use of drug-eluting balloons (DEB) reduces reste-
nosis rate after femoro-popliteal percutaneous transluminal
angioplasty (PTA) (6,7). Drug-eluting balloon use has
showed promising results in reducing restenosis recurrence
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accepted July 2, 2012.in coronary stents (8). At this moment, no data are available
on the use of DEB for the treatment of SFA-ISR.
The purpose of this prospective registry was to evaluate
the safety and efficacy of the use of DEB for the treatment
of ISR.
Methods
Study population. From December 2009 to December
2010, 39 patients underwent PTA for the treatment of
SFA-ISR in our institution (of a total of 308 SFA inter-
ventions). Patients were treated as of our standard practice
and included in a prospective registry. Follow-up protocol
was approved by the hospital institutional review board.
Concomitant therapy. All patients received aspirin (75 to
160 mg/day) and should have been receiving ticlopidine
(250 mg twice daily) for at least 7 days. Alternatively,
patients received clopidogrel preload (300 mg) 24 h before
procedure. Post-procedure, thyenopiridines were continued
for 30 days, whereas aspirin was continued for life. For
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to achieve activated clotting time
250 s.
PTA technique. All procedures
were performed percutaneously,
with the patient under local an-
esthesia. Vascular access was
achieved via contralateral common
femoral artery. A 6-F long sheath
was placed in cross-over technique
to achieve adequate support. Once
diagnostic angiography was com-
pleted, the wire was advanced in
the distal popliteal artery. A filter
for distal protection (Spider, EV3,
Plymouth, Minnesota) was placed distal to the stenosis at
operator discretion. All patients underwent balloon angio-
plasty (plain old balloon angioplasty) for at least 60 s, sizing
was 0.8:1 to the reference vessel diameter. Laser mediated
lesion debulking was used, to substitute balloon pre-
dilation, at operator discretion.
A final post-dilation, at least 180 s, was performed
with DEB (IN.PACT, Medtronic, Minneapolis, Minne-
sota); sizing was 1:1 to the reference vessel diameter. The
IN.PACT balloon has a surface-specific matrix coating
consisting of Paclitaxel combined with a hydrophilic
spacer (Freepac, Medtronic Invatec, Frauenfeld, Switzer-
land). Paclitaxel is an anti-proliferative drug, and the
maximum amount on a DEB is 8 mg. The hydrophilic
spacer, necessary to separate paclitaxel molecules and
facilitate drug elution into the arterial wall, is urea.
During inflation of the balloon the drug is almost
completely released (7).
The DEB-treated segment should begin 10 mm proximal
and extend toward 10 mm distal to the target SFA lesion. A
5-mm balloon overlap was allowed to obtain a uniform drug
elution in the treated vessel. Nitinol stent implantation was
allowed, for bail-out stenting (residual stenosis 30% or
flow-limiting dissections).
Post-procedural patient management. Femoral sheaths
were removed when activated clotting time was 150 s.
Access site hemostasis was achieved by manual compression
in all patients. A complete blood count was obtained before
the procedure and before hospital discharge.
Patient follow-up. Patients were evaluated through hospi-
tal discharge; at 30 days; and at 3, 6, and 12 months
post-procedure. Clinical follow-up was performed by a
clinical examination and duplex ultrasonography scan. Re-
peat angiography was performed when proximal flow veloc-
ity ratio (PVR) was between 2.4 and 5.0 (intermediate
restenosis) and when the patient had clinical symptoms or
5.0 (severe restenosis) regardless clinical symptoms and in
case of stent occlusion (5).
Classification of ISR. The ISR lesions were classified by





ISR  in-stent restenosis
PTA  percutaneous
transluminal angioplasty
PVR  proximal flow
velocity ratio
SFA  superficial femoral
artery
TLR  target lesion
revascularizationin length) ISR group, included lesions positioned at thestent body, the stent edge, or a combination of these sites;
class II, the diffuse (50 mm in length) ISR group, included
not only stent body lesions but also stent edge lesions; and
class III is the totally occluded ISR group (5).
Definitions. “Technical Success” was defined as the ability
to successfully perform PTA and DEB post-dilation with a
residual stenosis30%. “Procedural Success” was defined as
technical success without the occurrence of any in-hospital
major adverse cardiac and cerebrovascular events. “Primary
endpoint” was primary patency defined as PVR of 2.4
documented by duplex ultrasound at 12 months without
target lesion revascularization (TLR). “Secondary end-
points” included: 1) freedom from TLR at 1 year;
2) secondary patency at 1 year documented by duplex
(patency defined as a PVR 2.4); 3) clinical success as
defined by 1 category improvement in the Rutherford
scale from baseline (or 2 categories if there was pre-existing
tissue loss) at 1 year; and 4) hemodynamic success, defined
by a 0.1 improvement in the ankle-brachial index during the
period from baseline to 30 days post-procedure and no
deterioration 0.15 from the maximum early post-
rocedure level at 1 year. Stent fractures were classified as
inor, moderate, or severe (9). Below the knee artery was
onsidered patent if free of obstructive lesions determining
ngiographic stenosis 70%.
tatistical analysis. Nominal and categorical variables were
resented as contingency tables with frequencies and per-
entages. Continuous variables were reported as the mean
ith SD or median and interquartile ranges. Variables were
ompared by t test for normally distributed values (p  0.05
as considered statistically significant).
esults
atient clinical characteristics are summarized in Table 1.
Technical and procedural success was achieved in all 39
atients (100%). No procedure-related adverse events oc-
urred. In 4 patients the operator decided to perform
xcimer laser mediated plaque debulking. Distal protection
as adopted in 6 cases.
Patient Clinical CharacteristicsTable 1 Patient Clinical Characteristics
Male 32 (82.1)
Age (yrs) 65.9 9.6
Diabetes (%) 19 (48.7)
Hypertension (%) 36 (93.4)
Hypercholesterolemia 34 (87.2)
Smoking history 34 (87.2)
eGFR 30 (ml/min) 8 (20.5)
Rutherford class 2.9 0.7
BTK patent vessels
2 31 (79.5)
1 8 (20.5)N  39. Values are n (%) or mean  SD.
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Mean lesion length was 82.9  78.9 mm. This required the
se of almost 2 DEB/patients. Bail-out stenting was nec-
ssary in 4 patients due to flow limiting dissections at the
reated stent edges.
Of the 39 lesions treated, 30.8% were class I, 48.7% were
lass II, and 20.5% were class III. Stent fractures were all
inor and not geographically related to the restenosis site.
No major adverse cardiac and cerebrovascular events
ccurred in-hospital. Only 1 patient died, due to heart
ailure, determining a 2.56% rate of all-cause and cardio-
ascular mortality at 1 year.
The primary endpoint, primary patency, was obtained in
2.1% (n  35) (Fig. 1); in 3 patients, duplex scan—
performed at the 3-month follow-up in 1 patient and at
6-month follow-up in 2—showed a significant target lesion
restenosis. These patients underwent re-PTA of the target
lesion due to the presence of 2 focal (50 mm) and 1 diffuse
(50 mm) recurrent restenosis. At index procedure, 1 of
these was focal, and 2 were diffuse. Recurrent restenosis was
treated with DEB in 2 cases and with an endovascular graft
in the other case.
A further patient, 6 months post-procedure, underwent
an ipsilateral external iliac artery PTA. Thus, the result was
a 10.5% rate of target limb revascularization.
At 1 year, duplex assessment demonstrated no recurrent
restenosis (100% rate of secondary patency), Rutherford
class was 0.8  0.5 (baseline 2.9  0.7; p  0.05), no
amputation was necessary, and ankle-brachial index was
0.98  0.02 (baseline 0.77  0.09, p  0.05); thus clinical
and hemodynamic success was achieved in all patients.
In this small study, treatment of Type III ISR with DEB
was not associated with an increased rate of recurrent
restenosis, when compared with type I and II ISR. Unfor-
tunately the available data are not sufficient to perform any
Procedural CharacteristicsTable 2 Procedural Characteristics
Contralateral access 39 (100.0)
Pre-dilation 35 (89.8)
Distal protection 6 (15.4)
Excimer laser debulking 4 (10.3)
Stent diameter, mm 6 (6–6.5)
Stent length, mm 150 (95–262.5)
Lesion length, mm 82.9 78.9
Pre-dilation balloon diameter, mm 5 (4.5–5)
Pre-dilation balloon length, mm 120 (80–120)
DEB diameter, mm 6 (5–6)
Number of DEB 2 (1–2)
Cumulative DEB length, mm 160 (120–250)
Fractured stents 4 (10.3)
Bailout stenting (%) 4 (10.3)
Procedural success 39 (100)
N  39. Values are n (%), mean  SD, or median (interquartile range).
DEB  drug-eluting balloon(s); IQR  interquartile range.proper statistical correlation between treated lesion lengthand restenosis rate or bail-out stenting at index procedure
and restenosis rate.
Discussion
This study demonstrates that: 1) SFA-ISR can be safely
treated with PTA with DEB; and 2) the use of DEB is
associated with low rates of recurrences and good clinical
outcomes.
The incidence of SFA- ISR has been reported to occur in
up to 40% of patients within the first year (3,4). Experience
to date suggests that SFA-ISR can be treated with high
immediate procedural success, but durable long-term pa-
tency remains elusive. Balloon angioplasty for ISR lesions
does not provide acceptable patency rates at 2 years, which
are even worse when an occlusive class III ISR lesion is
treated (5). Cutting balloon angioplasty and debulking
strategies have been employed, but data are limited and not
encouraging (10–12).
Although randomized trials of DEB for femoropopliteal
disease included only a small number of patients with ISR
(6), dedicated trials of DEB for femoropopliteal ISR are still
ongoing. So far this is the largest report on the use of DEB
for the treatment of ISR.
A larger experience to date with drug-eluting technology
for femoropopliteal ISR comes from the Zilver PTX regis-
try, where a freedom from TLR at 12 months of 78% was
observed (13,14).
In our study a Class III ISR (occlusive) was not associated
with an increased recurrence risk. These data are particularly
important, because so far balloon angioplasty for occluded
ISR had been unfavorable.
Figure 1 Kaplan-Meier Curve
Representing Freedom From TLR
Curve shows freedom from target lesion revascularization (TLR) up to 1 year
after drug-eluting balloon–mediated percutaneous transluminal angioplasty
of superficial femoral artery in-stent restenosis. Dotted lines  95% confi-
dence interval.
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DEB for SFA In-Stent Restenosis October 30, 2012:1739–42Study limitations. The lack of a control group limits any
definitive conclusions that can be made with regard to the
optimal approach to SFA-ISR, and the results of this study
should be considered hypothesis-generating. A further lim-
itation of this study is that procedural technique was not
consistent throughout. The use of laser in a few cases
complicates analysis of the results at this moment; never-
theless, this could be a potential advantage in the future,
because this registry is still ongoing and could lead to a
potential investigation of the role of laser before DEB
treatment for SFA-ISR.
Conclusions
On the other end, the relevance of these data in the contem-
porary practice is somewhat increased because the availability
of DEB can change the paradigm for the treatment of
SFA-ISR.
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